ACCPL vs BALAXI: Stock Comparison
ACCPL is the larger company by market capitalisation. ACCPL shows a higher ROE, faster revenue growth and lower leverage, while BALAXI PHARMA shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ACCPL leads 9; BALAXI leads 1 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ACCPL | BALAXI |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | ACCPL | BALAXI |
|---|---|---|
| Live Price | — | ₹23.12 |
| Day Change | — | -1.24% |
| Volume | — | 22,486 |
| 52-Week High | — | ₹47.71 |
| 52-Week Low | — | ₹15.2 |
| Distance from 52W High | — | -51.54% |
Valuation
| Metric | ACCPL | BALAXI |
|---|---|---|
| Market Cap | ₹239 Cr | ₹127 Cr |
| P/E Ratio | — | 12.63x |
| P/B Ratio | — | 0x |
| EPS | ₹8.7 | ₹0.45 |
| Book Value | ₹49.22 | ₹45.12 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | ACCPL | BALAXI |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -25.76% |
| EPS Growth (TTM YoY) | 0% | -58.44% |
| Qtr Sales Growth | 104.93% | -80.68% |
| Qtr Profit Growth | 103.43% | -196.59% |
Profitability & Leverage
| Metric | ACCPL | BALAXI |
|---|---|---|
| ROE | 17.67% | 3.87% |
| ROCE | 16.34% | 4.42% |
| Net Margin | 0% | 0.52% |
| Operating Margin | 15.54% | 12.03% |
| Debt to Equity | 0.23x | 0.25x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ACCPL | BALAXI |
|---|---|---|
| Promoter Holding | 73.52% | 65.99% |
| FII Holding | 0% | 0% |
| DII Holding | 2.76%▲ 2.76 pp | 2.56% |
| Public Holding | 23.72%▼ 2.76 pp | 31.45% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ACCPL and BALAXI PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.